- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02634866
Cardiovascular Response to Exercise in Hypertension (ASSECURE)
Multivariate ASSEssment of CardiovascUlar Response to the Controlled Exercise in Patients With Hypertension - Prospective and Observational Study (ASSECURE Study)
Arterial hypertension (AH) is an important clinical social and economic problem, related to the increased cardiovascular risk. AH is associated with cardiovascular hemodynamic alterations, including left ventricular diastolic dysfunction (LVddf). In consequence of increased blood pressure, the effectiveness of LV as a blood pump decreases and the symptoms of heart failure (HF) may occur. Thus, the identification of noninvasive markers related with the progression from the asymptomatic AH to LVddf/HFpEF would be beneficial.
Another issue is that the diagnostic difficulties in patients with LVddf and HFpEF stem from the limited possibility to assess the hemodynamic response to exercise. Thus, there is a need for more detailed methods of cardiovascular monitoring while exercise testing.
We hypothesize that some new noninvasive hemodynamic parameters, characterizing left ventricular (LV) function and arterial stiffness, may help to predict the risk of cardiovascular events and future occurrence of LVddf/HFpEF. Moreover, we assume that cardiopulmonary exercise test (CPET), completed with new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry), would provide additional value in the assessment of the cardiovascular hemodynamic response to exercise.
The study is intended to verify these hypothesis.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Arterial hypertension (AH) is an important clinical social and economic problem, related to the increased cardiovascular risk.
AH is associated with cardiovascular hemodynamic alterations, including left ventricular diastolic dysfunction (LVddf). In consequence of increased blood pressure, the effectiveness of LV as a blood pump decreases and the symptoms of heart failure (HF), even with preserved ejection fraction (HFpEF), may occur. At the early stage, patients' complaints are not specific and difficult to clinical interpretation. As a consequence, these subjects frequently remain undiagnosed. Thus, the identification of noninvasive markers related with the progression from the asymptomatic AH to LVddf/HFpEF would be beneficial.
Another issue is that the diagnostic difficulties in patients with LVddf and HFpEF stem from the limited possibility to assess the hemodynamic response to exercise. Thus, there is a need for more detailed methods of cardiovascular monitoring while exercise testing.
The investigators hypothesize that some new noninvasive hemodynamic parameters, characterizing left ventricular (LV) function and arterial stiffness, may help to predict the risk of cardiovascular events and future occurrence of LVddf/HFpEF. Moreover, the investigators assume that cardiopulmonary exercise test (CPET), completed with new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry), would provide additional value in the assessment of the cardiovascular hemodynamic response to exercise.
Aims:
- The identification of the new markers of cardiovascular risk in patients with arterial hypertension..
- The identification of the new markers of progression from normal left ventricular diastolic function to left ventricular diastolic dysfunction.
- The identification of the new noninvasive markers of progression to symptomatic heart failure.
- The evaluation of the feasibility and usefulness of new methods of noninvasive hemodynamic monitoring (impedance cardiography and applanation tonometry) in the assessment of the cardiovascular hemodynamic response to exercise.
- Multivariate assessment of cardiovascular response to the controlled exercise, taking into account left ventricular diastolic function and symptoms of heart failure.
- The relation between laboratory markers of left ventricular remodeling with resting and exercise (noninvasive) hemodynamics.
The study will be performed in a prospective and observational design. No less than 120 hypertensive subjects will be enrolled.
After recruitment the following assessment will be performed:
- anamnesis and physical examination with anthropometrics (including body composition analysis with use of bioimpedance method);
- electrocardiogram;
- echocardiography (resting), including assessment of left ventricular systolic (2-D left ventricular ejection fraction, longitudinal strain) and diastolic function (including tissue Doppler imaging);
- impedance cardiography (resting);
- Applanation tonometry (resting);
- 24-h Holter-ekg (including heart rate variability analysis);
- 24-h ambulatory blood pressure monitoring;
- flow-mediated dilation of brachial artery (FMD);
- 6-minute walking test (6-MWT);
- Cardiopulmonary exercise test (CPET), supported by hemodynamic monitoring with impedance cardiography and applanation tonometry;
- Quality of life assessment (SF 36 questionnaire);
- Laboratory tests (including creatinine, urea, uric acid, lipids, glucose, microalbuminuria, N-terminal of the prohormone brain natriuretic peptide, galectin-3, copeptin, soluble ST2, Growth differentiation factor 15 (GDF-15), human tissue inhibitor of metalloproteinases 1 (TIMP-1), metalloproteinase 2 (MMP-2), metalloproteinase 9 (MMP-9), syndecan-1).
After 12 months (first control visit) and 24 months (second control visit) the echocardiography and clinical assessment (HF symptoms) will be performed to identify: 1/ patients with new onset LVDdf (among group N); 2/ patients with new onset HF (among group D)
Morover, the follow-up of min 48 months concerning cardiovascular events will be performed (as defined below)
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Mazovia
-
Warsaw, Mazovia, Polen, 04-141
- Military Institute of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- patients of either sex
- age 40-75 years
- arterial hypertension diagnosed ≥3 months before recruitment.
Exclusion Criteria:
- office blood pressure > 160/100 mmHg
- coronary artery disease
- systolic heart failure (LVEF below 45%) and/or severe heart defect (i.e. valvular disease)
- severe pulmonary diseases (COPD stage C/D, uncontrolled asthma, pulmonary hypertension, pulmonary embolism)
- chronic kidney disease (MDRD eGFR<60 ml/min/1.73m2)
- severe inflammatory disease
- severe mental and physical disorders
- polyneuropathy
- obesity with BMI > 40 kg/m2
- life expectancy less than 12 months in the opinion of the physician
- patients' refusal to participate.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Group N
The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
|
Group D
The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
|
Group D_HF
The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
complex end-point (death from cardiovascular causes and/or myocardial infarction and/or stroke and/or decompensated heart failure)
Tidsramme: 48 months
|
Any of the following cardiovascular events: death from cardiovascular causes and/or myocardial infarction and/or stroke and/or decompensated heart failure
|
48 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
death from any cause
Tidsramme: 48 months
|
48 months
|
death from cardiovascular causes
Tidsramme: 48 months
|
48 months
|
myocardial infarction
Tidsramme: 48 months
|
48 months
|
decompensated heart failure
Tidsramme: 48 months
|
48 months
|
stroke
Tidsramme: 48 months
|
48 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
new-onset of heart failure after 12 months (in groups N i D)
Tidsramme: 12 months
|
based on questionnaire
|
12 months
|
new-onset of heart failure after 24 months (in groups N i D)
Tidsramme: 24 months
|
based on questionnaire
|
24 months
|
new-onset of left ventricular diastolic dysfunction in echocardiography after 12 months (in group N)
Tidsramme: 12 months
|
12 months
|
|
new-onset of left ventricular diastolic dysfunction in echocardiography after 24 months (in group N)
Tidsramme: 24 months
|
24 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0000000336
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hypertensjon
-
University Hospital of CologneUkjentNAFLD; Hypertensjon, White-Coat Hypertension, Masked HypertensionTyskland
-
Karolinska InstitutetFullførtWhite Coat Hypertension
-
Clinical Hospital Centre ZagrebEuropean Society of HypertensionUkjentWhite Coat Hypertension | Blodtrykk | LivsstilsrisikoreduksjonIsrael, Hellas, Belgia, Tyskland, Armenia, Østerrike, Bulgaria, Kroatia, Tsjekkia, Estland, Italia, Libanon, Litauen, Nederland, Polen, Portugal, Romania, Serbia, Spania, Sverige, Ukraina, Storbritannia
-
Regional Hospital HolstebroFullførtSunn | White Coat Hypertension | Essensiell hypertensjonDanmark
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Aktiv, ikke rekrutterendeWhite Coat Hypertension | Hypertensjon, viktigForente stater
-
University of Alabama at BirminghamTroy UniversityFullførtHypertensjon | Hypertensjon, motstandsdyktig mot konvensjonell terapi | Ukontrollert hypertensjon | Hypertensjon, hvit pelsForente stater
-
PD Dr. Grégoire WuerznerSwiss National Science FoundationFullførtHypertensjon | Overvekt | White Coat Hypertension | Resistent hypertensjonSveits
-
University Hospital, ToursFullførtPTFE-dekkede stenter versus nakne stenter i TIPS (Transjugulær Intra-hepatisk Porto-systemisk shunt)Cirrhotic Portal HypertensionFrankrike
-
Sun Yat-sen UniversityFullførtHepatocellulært karsinom (HCC) | Cirrhotic Portal HypertensionKina